- Free from Publisher J Rosenstock, D Sugimoto, P Strange, JA … - Diabetes Care, 2006 - Am Diabetes Assoc RESULTS—A1C improvements from baseline were similar in both groups (−1.7 vs.
−1.5% for insulin glargine vs. rosiglitazone, respectively); however, when
baseline A1C was >9.5%, the reduction of A1C with insulin glargine was ... Cited by 100 - Related articles - BL Direct - All 8 versions
- ►onlinejacc.org [PDF] E Erdmann, JA Dormandy, B Charbonnel, M … - Journal of the American College of Cardiology, 2007 - Elsevier This analysis from the PROactive (PROspective pioglitAzone Clinical Trial In
macroVascular Events) study assesses the effects of pioglitazone on mortality
and macrovascular morbidity in patients with type 2 diabetes and a previous ... Cited by 81 - Related articles - BL Direct - All 13 versions
P Libby, J Plutzky - The American Journal of Cardiology, 2007 - Elsevier Patients with type 2 diabetes mellitus and/or the metabolic syndrome have
considerable cardiovascular risk. Treatment with 3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibitors (statins) and with antihypertensive and ... Cited by 58 - Related articles - All 32 versions
B Staels - Current Medical Research and Opinion®, 2005 - informahealthcare.com Département d'Athérosclérose – U.545 Inserm, Institut Pasteur de Lille, et
Université de Lille2, Lille, France ... Address for correspondence: Bart
Staels, Département d'Athérosclérose – U.545 Inserm, Institut Pasteur ... Cited by 54 - Related articles - All 6 versions
- ►columbiauniversity.org [PDF] B Kimmel, SE Inzucchi - Clinical Diabetes, 2005 - Am Diabetes Assoc Type 2 diabetes is a multifactorial metabolic disease characterized by
abnormalities at multiple organ sites. These defects include insulin resistance
and insulin deficiency. 1,2 The former is primarily represented by ... Cited by 46 - Related articles - All 5 versions
- ►diabetesjournals.org MA Deeg, JB Buse, RB Goldberg, DM Kendall, … - Diabetes Care, 2007 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—This is a prospective, randomized, double-blind,
multicenter, parallel-group study. After a 4-week placebo washout period,
patients randomized to PIO (n = 369) were treated with 30 mg qd for 12 ... Cited by 35 - Related articles - BL Direct - All 5 versions
- ►geyseco.info [PDF] E Selvin, S Bolen, HC Yeh, C Wiley, LM … - Archives of Internal Medicine, 2008 - Am Med Assoc Methods We searched MEDLINE, EMBASE, and the Cochrane Central Register of
Controlled Trials, from inception through January 19, 2006. Forty publications
of controlled trials that reported information on cardiovascular events ( ... Cited by 23 - Related articles - All 5 versions
D Einhorn, VR Aroda, RR Henry - Endocrinology and metabolism clinics of North America, 2004 - Elsevier The two drugs in this class that are currently available and approved by the
Food and Drug Administration for the treatment of type 2 diabetes mellitus
(T2DM) only are pioglitazone (Actos) and rosiglitazone (Avandia). The ... Cited by 18 - Related articles - BL Direct - All 3 versions
RB Goldberg - Current atherosclerosis reports, 2006 - Springer The thiazolidinediones, acting through peroxisome proliferator–activated
receptor γ (PPAR γ ), affect mul- tiple areas of metabolism. Of increasing
importance is the recognition that these agents affect lipoprotein ... Cited by 18 - Related articles - BL Direct - All 3 versions
- ►adisonline.com [PDF] R Rios-Vazquez, R Marzoa-Rivas, I Gil-Ortega … - American Journal of Cardiovascular Drugs, 2006 - ingentaconnect.com Page 1. Am J Cardiovasc Drugs 2006; 6 (4): 231-242 REVIEW ARTICLE 1175-3277/06/0004-
0231/$39.95/0 2006 Adis Data Information BV. All rights reserved. ... Cited by 15 - Related articles - BL Direct - All 7 versions
